Abstract |
The in-vitro biotransformation of the anxiolytic agent, RWJ-50172 was studied after incubation with rat hepatic S9 fraction in the presence of an NADPH-generating system, and incubating with Cunninghamella echinulata in soy-bean medium. Unchanged RWJ-50172 (80% of the sample in rat; 86% in fungi) plus 6 metabolites (M1-M6) were profiled, quantified and tentatively identified on the basis of API-MS/MS data. The metabolic pathways for RWJ-50172 are proposed, and the four metabolic pathways are: pyrido-oxidation (pathway A), phenylhydroxylation (B), dehydration (C) and reduction (D). Pathway A formed hydroxy-pyrido-RWJ-50172 (M1, 10% of the sample in both rat and fungi) as the only major metabolite, which further dehydrated to form dehydro-RWJ-50172 in trace quantities in rat. Pathway B produced hydroxyphenyl-RWJ-50172 (M2) in small amounts (4%) in rat, and in conjunction with step A formed dihydroxy-RWJ-50172 as a trace metabolite in rat. Step D produced a minor benzimidazole-reduced metabolite in fungi. RWJ-50172 is substantially metabolized by this rat hepatic S9 fraction and fungi.
|
Authors | Wu-Nan Wu, Linda A McKown, John L Melton, Allen B Reitz |
Journal | The Journal of pharmacy and pharmacology
(J Pharm Pharmacol)
Vol. 55
Issue 8
Pg. 1099-105
(Aug 2003)
ISSN: 0022-3573 [Print] England |
PMID | 12956899
(Publication Type: Journal Article)
|
Chemical References |
- 7-fluoro-1,2-dihydro-3-oxo-N-(2,6-diflurophenyl)pyrido(1,2-alpha)benzimidazole-4-carboxamide
- Amides
- Anti-Anxiety Agents
- Benzimidazoles
|
Topics |
- Amides
(metabolism, pharmacokinetics)
- Animals
- Anti-Anxiety Agents
(metabolism, pharmacokinetics)
- Benzimidazoles
(metabolism, pharmacokinetics)
- Biotransformation
- Cunninghamella
(enzymology, metabolism)
- In Vitro Techniques
- Male
- Microsomes, Liver
(metabolism)
- Rats
- Rats, Sprague-Dawley
|